Insider Selling: Q32 Bio (NASDAQ:QTTB) CFO Sells 3,995 Shares of Stock

Q32 Bio Inc. (NASDAQ:QTTB) CFO Lee Kalowski sold 3,995 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total transaction of $18,017.45. Following the completion of the sale, the chief financial officer owned 35,943 shares in the company, valued at $162,102.93. This represents a 10.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Lee Kalowski also recently made the following trade(s):

• On Tuesday, December 2nd, Lee Kalowski sold 9,072 shares of Q32 Bio stock. The stock was sold at an average price of $3.46, for a total transaction of $31,389.12.

Q32 Bio Trading Down 4.2%

QTTB stock traded down $0.20 during trading on Friday, hitting $4.56. 203,990 shares of the stock traded hands, compared to its average volume of 164,705. The stock has a market cap of $56.09 million, a price-to-earnings ratio of -1.33 and a beta of 0.16. Q32 Bio Inc. has a one year low of $1.35 and a one year high of $6.37. The company has a 50 day simple moving average of $3.78 and a 200 day simple moving average of $2.88.

Q32 Bio News Roundup

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long‑term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
• Neutral Sentiment: HC Wainwright published a multi‑year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
• Negative Sentiment: The analyst model shows substantial near‑term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short‑term investor sentiment.
• Negative Sentiment: Consensus full‑year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near‑term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on QTTB. HC Wainwright began coverage on Q32 Bio in a research report on Wednesday. They issued a “buy” rating and a $13.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Q32 Bio in a report on Friday, January 9th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $14.00.

Institutional Investors Weigh In On Q32 Bio

Institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd acquired a new position in shares of Q32 Bio during the fourth quarter valued at $68,000. Opaleye Management Inc. acquired a new position in Q32 Bio during the 4th quarter valued at about $708,000. ADAR1 Capital Management LLC bought a new position in shares of Q32 Bio in the 4th quarter valued at about $66,000. Jane Street Group LLC bought a new position in shares of Q32 Bio in the 4th quarter valued at about $84,000. Finally, HRT Financial LP grew its position in shares of Q32 Bio by 66.5% during the 4th quarter. HRT Financial LP now owns 24,698 shares of the company’s stock worth $81,000 after buying an additional 9,862 shares during the period. Institutional investors own 31.32% of the company’s stock.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.